{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:15:01Z","timestamp":1791321301114,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004794","name":"CNR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Limoges"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.antiviral.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T03:30:34Z","timestamp":1455075034000},"page":"115-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis"],"prefix":"10.1016","volume":"129","author":[{"given":"D.","family":"Andouard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Mazeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ligat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Couvreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pouteil-Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yasdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Deering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Viget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.02.004_bib1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jmv.20127","article-title":"Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection","volume":"73","author":"Alain","year":"2004","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.antiviral.2016.02.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.antiviral.2016.02.004_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11908-012-0292-2","article-title":"Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment","volume":"14","author":"Beam","year":"2012","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.antiviral.2016.02.004_bib5","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1038\/sj.bmt.1702361","article-title":"Development of a cytomegalovirus vector for somatic gene therapy","volume":"25","author":"Borst","year":"2000","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.antiviral.2016.02.004_bib6","doi-asserted-by":"crossref","first-page":"8320","DOI":"10.1128\/JVI.73.10.8320-8329.1999","article-title":"Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants","volume":"73","author":"Borst","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.02.004_bib10","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/AAC.43.6.1500","article-title":"Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS clinical trials group CMV laboratories","volume":"43","author":"Chou","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.02.004_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/375743","article-title":"Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus","volume":"188","author":"Chou","year":"2003","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.02.004_bib15","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1128\/JVI.72.7.5927-5936.1998","article-title":"Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments","volume":"72","author":"Cihlar","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.02.004_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1386-6532(03)00163-X","article-title":"Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy","volume":"29","author":"Ducancelle","year":"2004","journal-title":"J.\u00a0Clin. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2016.02.004_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/135965350601100416","article-title":"A\u00a0novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","volume":"11","author":"Ducancelle","year":"2006","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.antiviral.2016.02.004_bib20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2016.02.004_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/0471250953.bi0506s15","article-title":"Comparative protein structure modeling using modeller","author":"Eswar","year":"2006","journal-title":"Curr. Protoc. Bioinforma. Ed. Board"},{"key":"10.1016\/j.antiviral.2016.02.004_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jcv.2015.06.090","article-title":"Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay","author":"Fischer","year":"2015","journal-title":"J.\u00a0Clin. Virol."},{"issue":"12","key":"10.1016\/j.antiviral.2016.02.004_bib24","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1128\/AAC.49.12.4860-4866.2005","article-title":"New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in\u00a0vitro drug exposure","volume":"49","author":"Gilbert","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.02.004_bib25","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/AAC.00334-11","article-title":"Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either Ganciclovir or Foscarnet\u25bf","volume":"55","author":"Gilbert","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.02.004_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QCO.0b013e32834cfb58","article-title":"The biology of cytomegalovirus drug resistance","volume":"24","author":"Hakki","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.02.004_bib27","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.02.004_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2013.02.002","article-title":"Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model","volume":"98","author":"Hantz","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.02.004_bib29","doi-asserted-by":"crossref","first-page":"18193","DOI":"10.1074\/jbc.M602414200","article-title":"Crystal structure of the herpes simplex virus 1 DNA polymerase","volume":"281","author":"Liu","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.02.004_bib32","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J.\u00a0Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2016.02.004_bib33","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/07391102.2013.800001","article-title":"A\u00a03D structural model and dynamics of hepatitis C virus NS3\/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity","volume":"32","author":"Rimmert","year":"2014","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.antiviral.2016.02.004_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/prot.21005","article-title":"Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance","volume":"64","author":"Shi","year":"2006","journal-title":"Proteins"},{"key":"10.1016\/j.antiviral.2016.02.004_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-60761-652-8_30","article-title":"En passant mutagenesis: a two step markerless red recombination system","volume":"634","author":"Tischer","year":"2010","journal-title":"Methods Mol. Biol. Clifton N. J."},{"key":"10.1016\/j.antiviral.2016.02.004_bib36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1086\/368385","article-title":"Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis","volume":"187","author":"Weinberg","year":"2003","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.02.004_bib37","doi-asserted-by":"crossref","first-page":"25246","DOI":"10.1074\/jbc.M111.248864","article-title":"Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase","volume":"286","author":"Zahn","year":"2011","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T20:31:06Z","timestamp":1654288266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216300365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":25,"alternative-id":["S0166354216300365"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.02.004","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}